Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal squamous cell cancer.
about
Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.The Impact of HPV as an Etiological Factor in Gynecological and Oropharyngeal CancerThe Impact of Post-transcriptional Control: Better Living Through RNA Regulons
P2860
Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal squamous cell cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Phase I study of induction che ...... aryngeal squamous cell cancer.
@en
Phase I study of induction che ...... aryngeal squamous cell cancer.
@nl
type
label
Phase I study of induction che ...... aryngeal squamous cell cancer.
@en
Phase I study of induction che ...... aryngeal squamous cell cancer.
@nl
prefLabel
Phase I study of induction che ...... aryngeal squamous cell cancer.
@en
Phase I study of induction che ...... aryngeal squamous cell cancer.
@nl
P2093
P2860
P356
P1433
P1476
Phase I study of induction che ...... haryngeal squamous cell cancer
@en
P2093
David G Pfister
Eric J Sherman
Matthew G Fury
Nora Katabi
Sofia S Haque
P2860
P304
P356
10.1002/HED.24938
P50
P577
2017-09-30T00:00:00Z